Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA

Harbour BioMed, a global biopharmaceutical company, has announced that the National Medical Products Administration (NMPA) of China has accepted its Biologics License Application (BLA) for batoclimab in the treatment of generalized myasthenia gravis (gMG). This marks the first BLA accepted by NMPA since Harbour BioMed's establishment. Batoclimab is an innovative therapy targeting anti-FcRn treat..